Cargando…
A Hexasaccharide Containing Rare 2‐O‐Sulfate‐Glucuronic Acid Residues Selectively Activates Heparin Cofactor II
Glycosaminoglycan (GAG) sequences that selectively target heparin cofactor II (HCII), a key serpin present in human plasma, remain unknown. Using a computational strategy on a library of 46 656 heparan sulfate hexasaccharides we identified a rare sequence consisting of consecutive glucuronic acid 2‐...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347859/ https://www.ncbi.nlm.nih.gov/pubmed/28124818 http://dx.doi.org/10.1002/anie.201609541 |
_version_ | 1782514126736588800 |
---|---|
author | Sankarayanarayanan, Nehru Viji Strebel, Tamara R. Boothello, Rio S. Sheerin, Kevin Raghuraman, Arjun Sallas, Florence Mosier, Philip D. Watermeyer, Nicholas D. Oscarson, Stefan Desai, Umesh R. |
author_facet | Sankarayanarayanan, Nehru Viji Strebel, Tamara R. Boothello, Rio S. Sheerin, Kevin Raghuraman, Arjun Sallas, Florence Mosier, Philip D. Watermeyer, Nicholas D. Oscarson, Stefan Desai, Umesh R. |
author_sort | Sankarayanarayanan, Nehru Viji |
collection | PubMed |
description | Glycosaminoglycan (GAG) sequences that selectively target heparin cofactor II (HCII), a key serpin present in human plasma, remain unknown. Using a computational strategy on a library of 46 656 heparan sulfate hexasaccharides we identified a rare sequence consisting of consecutive glucuronic acid 2‐O‐sulfate residues as selectively targeting HCII. This and four other unique hexasaccharides were chemically synthesized. The designed sequence was found to activate HCII ca. 250‐fold, while leaving aside antithrombin, a closely related serpin, essentially unactivated. This group of rare designed hexasaccharides will help understand HCII function. More importantly, our results show for the first time that rigorous use of computational techniques can lead to discovery of unique GAG sequences that can selectively target GAG‐binding protein(s), which may lead to chemical biology or drug discovery tools. |
format | Online Article Text |
id | pubmed-5347859 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-53478592017-03-23 A Hexasaccharide Containing Rare 2‐O‐Sulfate‐Glucuronic Acid Residues Selectively Activates Heparin Cofactor II Sankarayanarayanan, Nehru Viji Strebel, Tamara R. Boothello, Rio S. Sheerin, Kevin Raghuraman, Arjun Sallas, Florence Mosier, Philip D. Watermeyer, Nicholas D. Oscarson, Stefan Desai, Umesh R. Angew Chem Int Ed Engl Communications Glycosaminoglycan (GAG) sequences that selectively target heparin cofactor II (HCII), a key serpin present in human plasma, remain unknown. Using a computational strategy on a library of 46 656 heparan sulfate hexasaccharides we identified a rare sequence consisting of consecutive glucuronic acid 2‐O‐sulfate residues as selectively targeting HCII. This and four other unique hexasaccharides were chemically synthesized. The designed sequence was found to activate HCII ca. 250‐fold, while leaving aside antithrombin, a closely related serpin, essentially unactivated. This group of rare designed hexasaccharides will help understand HCII function. More importantly, our results show for the first time that rigorous use of computational techniques can lead to discovery of unique GAG sequences that can selectively target GAG‐binding protein(s), which may lead to chemical biology or drug discovery tools. John Wiley and Sons Inc. 2017-01-26 2017-02-20 /pmc/articles/PMC5347859/ /pubmed/28124818 http://dx.doi.org/10.1002/anie.201609541 Text en © 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Communications Sankarayanarayanan, Nehru Viji Strebel, Tamara R. Boothello, Rio S. Sheerin, Kevin Raghuraman, Arjun Sallas, Florence Mosier, Philip D. Watermeyer, Nicholas D. Oscarson, Stefan Desai, Umesh R. A Hexasaccharide Containing Rare 2‐O‐Sulfate‐Glucuronic Acid Residues Selectively Activates Heparin Cofactor II |
title | A Hexasaccharide Containing Rare 2‐O‐Sulfate‐Glucuronic Acid Residues Selectively Activates Heparin Cofactor II |
title_full | A Hexasaccharide Containing Rare 2‐O‐Sulfate‐Glucuronic Acid Residues Selectively Activates Heparin Cofactor II |
title_fullStr | A Hexasaccharide Containing Rare 2‐O‐Sulfate‐Glucuronic Acid Residues Selectively Activates Heparin Cofactor II |
title_full_unstemmed | A Hexasaccharide Containing Rare 2‐O‐Sulfate‐Glucuronic Acid Residues Selectively Activates Heparin Cofactor II |
title_short | A Hexasaccharide Containing Rare 2‐O‐Sulfate‐Glucuronic Acid Residues Selectively Activates Heparin Cofactor II |
title_sort | hexasaccharide containing rare 2‐o‐sulfate‐glucuronic acid residues selectively activates heparin cofactor ii |
topic | Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347859/ https://www.ncbi.nlm.nih.gov/pubmed/28124818 http://dx.doi.org/10.1002/anie.201609541 |
work_keys_str_mv | AT sankarayanarayanannehruviji ahexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT strebeltamarar ahexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT boothellorios ahexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT sheerinkevin ahexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT raghuramanarjun ahexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT sallasflorence ahexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT mosierphilipd ahexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT watermeyernicholasd ahexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT oscarsonstefan ahexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT desaiumeshr ahexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT sankarayanarayanannehruviji hexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT strebeltamarar hexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT boothellorios hexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT sheerinkevin hexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT raghuramanarjun hexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT sallasflorence hexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT mosierphilipd hexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT watermeyernicholasd hexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT oscarsonstefan hexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii AT desaiumeshr hexasaccharidecontainingrare2osulfateglucuronicacidresiduesselectivelyactivatesheparincofactorii |